Investor Calendar is powered by PrecisionIR, the leading webcaster of official investor relations events, and offers free access to live and archived corporate communications
November 4, 2009 - 4:15 PM Eastern
Chembio Diagnostics, Inc. Third Quarter 2009 Financial Results Webcast
Information contained in this webcast is current as of the date and time first presented. The use of pop-up blocking or firewall software may prevent you from accessing this webcast. Please temporarily disable any of these products you may have while attempting to access this event.
About The Company
Chembio Diagnostics develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $10 billion point-of-care testing market. Chembio’s two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by Alere, Inc. (formerly, Inverness Medical Innovations, Inc.). Chembio markets its HIV STAT-PAK® line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio has developed a patented point-of-care test platform technology, the Dual Path Platform (DPP®) technology, which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP®. Headquartered in Medford, NY, with approximately 170 employees, Chembio is licensed by the U.S. Food and Drug Administration (FDA) as well as the U. S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13.485. For additional information please visit www.chembio.com.
A part of PrecisionIR Group, www.PrecisionIR.com
9011 Arboretum Parkway, Suite 295, Richmond, VA 23236
2 Lansdowne Road, Croydon, CR9 2ER, UK (Registered in England No 2394368)
Strandvägen 7A, 114 56 Stockholm, Sweden